Navigation Links
Amarin Announces Proposed Public Offering of American Depositary Shares
Date:1/5/2011

expertise in lipid science focused on the treatment of cardiovascular disease. The Company's lead product candidate is AMR101, the active ingredient in which is ethyl-EPA (ethyl icosapentate). On November 29, 2010, the Company reported positive, statistically significant top-line results from the MARINE trial, the first of its Phase 3 clinical trials of AMR101. In the MARINE trial, AMR101 was investigated as a treatment for very high triglycerides (>500 mg/dL). AMR101 is presently being investigated in a second Phase 3 clinical trial, the ANCHOR trial, for the treatment of patients on statin therapy with high triglycerides (≥200 and <500mg/dL) with mixed dyslipidemia. The MARINE trial was, and the ANCHOR trial currently is, conducted under Special Protocol Assessment (SPA) agreements with the U.S. Food and Drug Administration (FDA). Amarin also has next-generation lipid candidates under evaluation for preclinical development. Investor Contact Information: John F. Thero President In U.S.: +1 (860) 572-4979 investor.relations@amarincorp.comLee M. Stern The Trout Group In U.S.: +1 (646) 378-2922 lstern@troutgroup.comMedia Contact Information: David Schull or Martina Schwarzkopf, Ph.D. Russo Partners In U.S.: +1 (212) 845-4271 or +1 (212) 845-4292 (office) +1 (347) 591-8785 (mobile) david.schull@russopartnersllc.commartina.schwarzkopf@russopartnersllc.comMark Swallow or David Dible Citigate Dewe Rogerson In U.K.: +44 (0)207 638 9571 mark.swallow@citigatedr.co.ukDisclosure NoticeThis press release contains forward-looking statements, within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements that are not historica
'/>"/>

SOURCE Amarin Corporation plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
2. Regeneron Announces Presentation at the 29th Annual J.P. Morgan Healthcare Conference
3. Medivation Announces Participation in 29th Annual J.P. Morgan Healthcare Conference
4. Gov. Jindal Announces Myriant Technologies to Begin Construction of New, Sustainable Specialty Chemical Plant in Lake Providence
5. Neogen Corporation Announces 2nd Quarter Results Conference Call
6. El Camino Hospital Announces First Implant in Clinical Trial to Evaluate Revolutionary Heart Valve Procedure
7. Aethlon Medical Announces Washington, DC Shareholder Presentation
8. InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbrietâ„¢ (Pirfenidone) in Europe
9. Sequenom Announces Publication Acceptance of Manuscript From Trisomy 21 R&D Verification Study
10. Talecris Biotherapeutics Announces Jury Verdict in Contract Dispute
11. China Cord Blood Corporation Announces Completion of Warrant Exchange
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 26, 2014 "Ischemic Stroke and ... provides data on the Ischemic Stroke and Cerebral ... information and data relating to the clinical trials ... full global Ischemic Stroke Research Report 2014 at: ... of the trial numbers and their recruitment status ...
(Date:7/25/2014)... 25, 2014 Amgen (NASDAQ: AMGN ... a $0.61 per share dividend for the third quarter ... 5, 2014, to all stockholders of record as of ... About Amgen Amgen is committed to unlocking ... illnesses by discovering, developing, manufacturing and delivering innovative human ...
(Date:7/25/2014)... each person,s digestive tract. Scientists believe that some of ... infections, but their role in human health is not ... role of these bacteria, a team of researchers led ... in the bacterial populations of two research subjects over ... 25 issue of the journal Genome Biology , ...
(Date:7/25/2014)... the University of Leicester has furthered our understanding ... to create new materials using nanosized ,building blocks,. ... the prestigious academic journal Physical Review Letters ... in rich detail the structure and internal atomic ... molecule and a single helium atom. , The ...
Breaking Biology Technology:Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 3Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3Monitoring the rise and fall of the microbiome 2Monitoring the rise and fall of the microbiome 3Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 2Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 3
... OSLO, Norway, June 17 , ... Shown to Improve Remission Rates and,Reduce Short-Term Mortality Compared ... Pharma ASA (OSE: CLAVIS) today announces positive final results,from ... drug, elacytarabine,(CP-4055), in patients with late-stage acute myeloid leukaemia ...
... ... and Communications Convergence , ... San Diego, CA (PRWEB) June 17, 2009 -- CommNexus and Leap ... unlimited wireless services, today announce their support for EvoNexus, a non-profit incubator dedicated to ...
... by Advanced Cell Technology,s Chief Scientist, Robert Lanza yields answers ... 16 MSNBC.com featured today Dr. Robert Lanza,s book (co-authored ... Consciousness are the Keys to Understanding the True Nature of ... Log." The article by Science Editor Alan Boyle includes ...
Cached Biology Technology:Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 2Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 3Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 4Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 5Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 6Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 7San Diego Wireless Heavyweight Leap Wireless Supports New Start-up Incubator 2San Diego Wireless Heavyweight Leap Wireless Supports New Start-up Incubator 3San Diego Wireless Heavyweight Leap Wireless Supports New Start-up Incubator 4MSNBC Publishes Free Online Abridgment of 'Biocentrism' 2MSNBC Publishes Free Online Abridgment of 'Biocentrism' 3
(Date:7/25/2014)... N.Y., July 25, 2014 In the first broad-scale estimate ... Service scientists and collaborators calculated that trees are saving ... 670,000 incidences of acute respiratory symptoms. , While trees, ... of less than 1 percent, the impacts of that ... of the reduced air pollution at nearly $7 billion ...
(Date:7/25/2014)... colonial era, 100,000s of people lived on the land ... fire to control the availability of plants they used ... to use fire to maintain desired habitat and natural ... Forest Service,s Pacific Southwest Station, will lead a ... Refuge during the Ecological Society of America,s 99th Annual ...
(Date:7/25/2014)... burn scars on this false-color image from the Terra satellite ... year,s rash of wildfires in Eastern Russia. The burn ... green background. The wildfires have broken across the remote ... in this false-color image from the MODIS instrument, it ... fires that continue. Two recent image features noted below show ...
Breaking Biology News(10 mins):First national study finds trees saving lives, reducing respiratory problems 2Fire ecology manipulation by California native cultures 2Fire ecology manipulation by California native cultures 3
... his Jan. 23 State of the Union address, President George ... foreign oil by requiring the production of 35 billion gallons ... five times the current target set by Congress of 7.5 ... are fuels derived from biological material. Currently, the main biofuel ...
... Fellow Michael Courtney has identified a new molecular pathway ... degeneration of brain cells, which in turn plays an ... Alzheimer's disease, epilepsy and stroke. Courtney and his team, ... University of Kuopio, joined forces with Docent Eleanor Coffey's ...
... in their diet could reduce their chances of developing cardiovascular disease ... today. , Researchers in Boston also found a reduction in salt ... up to a fifth. , Cardiovascular disease refers ... for example a stroke or heart disease. While there is ...
Cached Biology News:Cellulosic ethanol: Fuel of the future? 2Cellulosic ethanol: Fuel of the future? 3Researchers hot on the trail of brain cell degeneration 2Eating less salt could prevent cardiovascular disease 2
Glycerokinase; from Bacillus stearothermophilus...
... drives of VARIOMAG Magnetic Stirrers operate without ... or mechanical bearings, making VARIOMAG Magnetic Stirrers ... VARIOMAG inductive drive can be hermetically sealed, ... microorganisms. This is why VARIOMAG Magnetic Stirrers ...
...
... Ascent FL is equipped ... luminometric measurement technologies that ... of advanced features of ... Ascent. Fluoroskan Ascent FL ...
Biology Products: